trazodone has been researched along with Weight Reduction in 2 studies
Trazodone: A serotonin uptake inhibitor that is used as an antidepressive agent. It has been shown to be effective in patients with major depressive disorders and other subsets of depressive disorders. It is generally more useful in depressive disorders associated with insomnia and anxiety. This drug does not aggravate psychotic symptoms in patients with schizophrenia or schizoaffective disorders. (From AMA Drug Evaluations Annual, 1994, p309)
trazodone : An N-arylpiperazine in which one nitrogen is substituted by a 3-chlorophenyl group, while the other is substituted by a 3-(3-oxo[1,2,4]triazolo[4,3-a]pyridin-2(3H)-yl)propyl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Early human pharmaco-EEG and subsequent sleep laboratory studies identified trazodone, a 5-HT(2) antagonist and 5-HT reuptake inhibitor (SARI), as an antidepressant with therapeutic effects on its target symptoms depressed mood, anxiety and insomnia." | 9.10 | Confirmation of the neurophysiologically predicted therapeutic effects of trazodone on its target symptoms depression, anxiety and insomnia by postmarketing clinical studies with a controlled-release formulation in depressed outpatients. ( Anderer, P; Arnold, O; Saletu, B; Saletu-Zyhlarz, GM, 2003) |
| "Early human pharmaco-EEG and subsequent sleep laboratory studies identified trazodone, a 5-HT(2) antagonist and 5-HT reuptake inhibitor (SARI), as an antidepressant with therapeutic effects on its target symptoms depressed mood, anxiety and insomnia." | 5.10 | Confirmation of the neurophysiologically predicted therapeutic effects of trazodone on its target symptoms depression, anxiety and insomnia by postmarketing clinical studies with a controlled-release formulation in depressed outpatients. ( Anderer, P; Arnold, O; Saletu, B; Saletu-Zyhlarz, GM, 2003) |
| "Fluoxetine and trazodone were compared in a double-blind, randomized, parallel, 6-week trial in 43 outpatients with major depression after a 1-week single-blind placebo period." | 2.66 | Fluoxetine versus trazodone in the treatment of outpatients with major depression. ( Debus, JR; Himmel, C; Polatin, P; Rush, AJ; Tyler, D; Weissenburger, J, 1988) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (50.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Saletu-Zyhlarz, GM | 1 |
| Anderer, P | 1 |
| Arnold, O | 1 |
| Saletu, B | 1 |
| Debus, JR | 1 |
| Rush, AJ | 1 |
| Himmel, C | 1 |
| Tyler, D | 1 |
| Polatin, P | 1 |
| Weissenburger, J | 1 |
2 trials available for trazodone and Weight Reduction
| Article | Year |
|---|---|
Confirmation of the neurophysiologically predicted therapeutic effects of trazodone on its target symptoms depression, anxiety and insomnia by postmarketing clinical studies with a controlled-release formulation in depressed outpatients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antidepressive Agents, Second-Generation; Anxiety; Bipol | 2003 |
Fluoxetine versus trazodone in the treatment of outpatients with major depression.
Topics: Ambulatory Care; Clinical Trials as Topic; Depressive Disorder; Dizziness; Double-Blind Method; Fluo | 1988 |